Yutaka Susuta

409 total citations
15 papers, 339 citations indexed

About

Yutaka Susuta is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Neurology. According to data from OpenAlex, Yutaka Susuta has authored 15 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Surgery and 3 papers in Neurology. Recurrent topics in Yutaka Susuta's work include Diabetes Treatment and Management (4 papers), Parkinson's Disease Mechanisms and Treatments (3 papers) and Diabetes Management and Research (3 papers). Yutaka Susuta is often cited by papers focused on Diabetes Treatment and Management (4 papers), Parkinson's Disease Mechanisms and Treatments (3 papers) and Diabetes Management and Research (3 papers). Yutaka Susuta collaborates with scholars based in Japan, United States and France. Yutaka Susuta's co-authors include Kazuoki Kondo, Toru Yoshinari, Nobuya Inagaki, Nobuko Maruyama, Yukio Takahashi, Yoshiya Tanaka, Tsutomu Takeuchi, Shinsuke Inoue, Kimihiro Okubo and Noriko Sato and has published in prestigious journals such as PLoS ONE, Diabetes Obesity and Metabolism and Journal of Gastroenterology.

In The Last Decade

Yutaka Susuta

12 papers receiving 334 citations

Peers

Countries citing papers authored by Yutaka Susuta

Since Specialization

Citations

This map shows the geographic impact of Yutaka Susuta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yutaka Susuta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yutaka Susuta more than expected).

Fields of papers citing papers by Yutaka Susuta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yutaka Susuta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yutaka Susuta. The network helps show where Yutaka Susuta may publish in the future.

Co-authorship network of co-authors of Yutaka Susuta

This figure shows the co-authorship network connecting the top 25 collaborators of Yutaka Susuta. A scholar is included among the top collaborators of Yutaka Susuta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yutaka Susuta. Yutaka Susuta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder 2024 ·Journal of Clinical Psychopharmacology ·(unknown), Yutaka Susuta, (unknown), Yumi Watanabe, Koichiro Watanabe	0
2	Safety and effectiveness of fingolimod in Japanese patients with multiple sclerosis: Results of a post‐marketing surveillance study 2024 ·Clinical and Experimental Neuroimmunology ·Noriko Sato, (unknown), (unknown), Yutaka Susuta, (unknown), (unknown), (unknown), Jun‐ichi Kira	0
3	Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance 2024 ·Advances in Therapy ·Toshifumi Hibi∥, Shunsei Hirohata, Tadakazu Hisamatsu, Hirotoshi Kikuchi, Mitsuhiro Takeno, Noriko Sato, Naomi Mizuno, (unknown), Yutaka Susuta, Yoshiaki Ishigatsubo	4
4	Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia 2024 ·Journal of Clinical Psychopharmacology ·Yumi Watanabe, Yutaka Susuta, (unknown), (unknown), Nobuhisa Kanahara	0
5	Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double‐blind, placebo‐controlled study (J‐KINECT) 2022 ·Psychiatry and Clinical Neurosciences ·(unknown), Koichiro Watanabe, Kazuoki Kondo, (unknown), Hajime Sakamoto, Yutaka Susuta, (unknown), Yumi Watanabe	9
6	Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis 2021 ·Journal of Gastroenterology ·Katsuyoshi Matsuoka, Hirono Ishikawa, Takeo Nakayama, Yusuke Honzawa, Atsuo Maemoto, Fumihito Hirai, Fumiaki Ueno, Noriko Sato, Yutaka Susuta, Toshifumi Hibi∥	11
7	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes 2021 ·Circulation Reports ·Tomoya Ueda, Shu Kasama, (unknown), Tomoya Nakano, (unknown), Yoshinobu MORIKAWA, Hiroyuki Kawata, Akiomi Yoshihisa, Masafumi Nakayama, Sei Komatsu, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami, Yasushi Okada, Hiroyuki Tanaka, Yutaka Susuta, Masato Kasahara, Kenichi Tsujita, Yasuchika Takeishi, Yoshihiko Saito, (unknown)	23
8	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study 2020 ·Lupus ·Yoshiya Tanaka, Kazuoki Kondo, (unknown), (unknown), Yutaka Susuta, Shinsuke Inoue, Tsutomu Takeuchi	19
9	Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan 2019 ·BMC Pediatrics ·Hitoshi Tajiri, Katsuhiro Arai, Seiichi Kagimoto, Reiko Kunisaki, Nobuyuki Hida, Noriko Sato, Hiroshi Yamada, (unknown), Yutaka Susuta, (unknown), Kazuoki Kondo, Toshifumi Hibi∥	4
10	Rationale and Design of the CANONICAL Study　― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ― 2019 ·Circulation Reports ·Shu Kasama, Tohru Masuyama, Shiro Uemura, Yukihito Sato, Shinya Hiramitsu, Izuru Masuda, Kazuhiro Yamamoto, Sei Komatsu, Toshihisa Anzai, Kunihiro Nishimura, Tomoya Ueda, Masato Kasahara, Hiroyuki Tanaka, Yutaka Susuta, Yoshihiko Saito	6
11	Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan 2018 ·PLoS ONE ·Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, (unknown), Yutaka Susuta, (unknown), Kazuoki Kondo, Toshifumi Hibi∥	4
12	Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis 2015 ·Expert Opinion on Pharmacotherapy ·Kimihiro Okubo, (unknown), (unknown), Yutaka Susuta, (unknown)	9
13	4. Safety Risk Evaluation Methodology in Detecting the Medicine Concomitant Use Risk which might Cause Critical Drug Rash 2014 ·Yutaka Susuta, Yukio Takahashi	19
14	Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study 2014 ·Expert Opinion on Pharmacotherapy ·Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari, (unknown), Yutaka Susuta, (unknown)	111
15	Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study 2013 ·Diabetes Obesity and Metabolism ·Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari, Nobuko Maruyama, Yutaka Susuta, (unknown)	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact